Stocks
Intra-Cellular Therapies (ITCI) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 12 725% | 24 663% | 27 275% | 17 316% | 66 967% | 68 755% | |||
| Changes by years, y/y, % | -21 054pp | +11 938pp | +2 612pp | -9 960pp | +49 652pp | +14.7% | |||
Intra-Cellular Therapies. R&D/CAPEX, %
Intra-Cellular Therapies. R&D/CAPEX, changes, pp
Intra-Cellular Therapies (ITCI) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2022Q4 | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | LTM ? | |||
| R&D/CAPEX, % | 120 936% | 15 504% | 5 077 400% | 68 755% | ||||
| Changes by years, y/y, % | -2 250 972pp | -5 131pp | -31 330pp | -12 936pp | +4 956 464pp | |||
| Changes by quarters, q/q, % | +92 496pp | -120 936pp | +5 061 896pp | |||||
